Get Live Data

Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Firering Strategic Minerals : from explorer to producer
Firering Strategic Minerals: From explorer to producerView Video

Latest Share Chat

  2. Share Prices
  3. Avacta Group Share Price
  4. Avacta Group Share News
  5. IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Pin to quick picksAvacta Group Share News (AVCT)

Avacta Group Information

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 39.50
Ask: 40.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.532%)
Open: 40.00
High: 41.25
Low: 40.00
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Wed, 01st May 2024 11:53

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to chief executive officer from head of Research & Development. Coughlin has been an Avacta board member since March 2022 and head of R&D since this past February. She replaces Alastair Smith, who steps down on Tuesday after 19 years as CEO. Coughlin was CEO of Cytolmmune Therapeutics, which develops cell therapy solutions from a facility in Puerto Rico. She also has worked at Pfizer Inc and Novartis AG.

Current stock price: 44.40 pence

12-month change: down 63%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
8 Apr 2022 16:17

Avacta joint venture enters new immune model collaboration

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Friday that AffyXell Therapeutics - its joint venture with Daewoong Pharmaceutical - has entered into a collaboration agreement with Chinese biological drugs developer Biocytogen and the Korea Non-Clinical Technology Solution Center (KNTSC).

Read more
8 Apr 2022 11:28

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
8 Apr 2022 10:37

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

Read more
6 Apr 2022 10:23

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.

Read more
16 Mar 2022 13:02

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.

Read more
16 Mar 2022 11:38

Avacta sells veterinary division to Vimian for up to GBP2.3 million

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.

Read more
3 Feb 2022 12:31

Avacta moves to next dose in first-in-human chemotherapy trial

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.

Read more
3 Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta shares up 12% after chemotherapy drug advances to next stage

Read more
18 Jan 2022 14:36

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.

Read more
18 Jan 2022 13:52

Avacta selects potential tumour treatment for preclinical development

Avacta selects potential tumour treatment for preclinical development

Read more
18 Jan 2022 10:58

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

Read more
10 Jan 2022 12:16

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Read more
10 Jan 2022 12:08

Abingdon Health plunges after Avacta stops selling Covid-19 test

Abingdon Health plunges after Avacta stops selling Covid-19 test

Read more
10 Jan 2022 11:29

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Read more
10 Jan 2022 11:05

Shares plummet as Avacta pauses sale of lateral flow tests

(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.